RIDGEFIELD, Conn., Feb. 16, 2017 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved SPIRIVA RESPIMAT for the long-term ...

SPIRIVA RESPIMAT Inhalation Spray is now available by prescription through retail pharmacies across the United States for the long-term, once-daily maintenance treatment of bronchospasm associated ...

Boehringer Ingelheim announced that Spiriva Respimat (tiotropium bromide) is now available for the long-term maintenance treatment of asthma in patients ages ≥12 years. Boehringer Ingelheim announced ...

Tiotropium as Asthma Add-On Treatment Shows Promise Boehringer Ingelheim announced that the Food and Drug Administration (FDA) has approved Spiriva Respimat (tiotropium bromide) inhalation spray for ...

The FINANCIAL — Boehringer Ingelheim on September 16 announced that the U.S. Food and Drug Administration (FDA) approved SPIRIVA Respimat (tiotropium bromide) Inhalation Spray for use in the treatment ...

Boehringer Ingelheim is celebrating after the US Food and Drug Administration approved the mist version of its chronic obstructive pulmonary disease blockbuster Spiriva. Boehringer Ingelheim is ...

MONTREAL — Spiriva Respimat, as an add-on to inhaled corticosteroids or long-acting beta2 agonists, reduced the risk for severe asthma exacerbation in patients across severities of symptomatic asthma ...

-- Patients to Benefit From Easy-to-Use Inhaler With Enhanced Drug Delivery Boehringer Ingelheim and Pfizer today announced successful completion of the approval process for authorisation to market ...

RIDGEFIELD, Conn., March 29, 2018 /PRNewswire/ -- Boehringer Ingelheim announced today that data from the DYNAGITO trial, a 52-week study involving more than 7,800 people across a broad range of COPD ...

RIDGEFIELD, Conn., Oct. 11, 2018 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) approved new labeling for Stiolto Respimat (tiotropium bromide & ...

Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please ...

FDA recently accepted sNDA filing to review data from DYNAGITO trial for inclusion in Stiolto Respimat label A COPD exacerbation, or a flare-up, is a sudden worsening of symptoms, such as increased ...